Cyprotex (LSE: CRX) today announces it has entered into a new agreement with the pharmaceutical division of Belgian-based Solvay, the international chemicals and pharmaceuticals group, to provide drug discovery support using its Cloe Screen™ technology.
Under the agreement, Cyprotex will screen compounds for Solvay Pharmaceuticals GMBH and Solvay Pharmaceuticals B.V., and provide valuable information on their absorption, distribution, metabolism and excretion (ADME) properties. This information will be used by Solvay Pharmaceuticals to prioritise the best compounds to promote through their discovery process and to guide drug design process in order to maximise the chances of producing a successful drug.
Solvay Pharmaceuticals selected Cyprotex to perform this work after they were satisfied that Cloe Screen™ could consistently deliver high quality data within rapid turnaround times following a series of evaluations.
Dieter Ziegler, Research Program Manager at Solvay, said "We have enjoyed working with the Cyprotex team who have impressed us with quality data coupled with personal observations from their principal scientists regarding our compounds which we find extremely helpful. "
Commenting on the agreement, Robert Morrisson Atwater, CEO of Cyprotex plc, said: "It is exciting to see that Cyprotex's services are being adopted by a wide range of biotechnology and pharmaceutical companies. Yet again, we have passed the very stringent quality criteria that our customers demand, and I am delighted that Solvay, an exciting international pharmaceutical company, has recognised the value Cyprotex can bring to their drug discovery programs."
For further information:
Robert Morrisson Atwater, Chief Executive Officer
Tel: +44 (0) 1625 505100
Henry Harrison-Topham / Heather Salmond
Bankside Consultants Limited
Tel: +44 (0) 20 7444 4140